Soligenix
SNGX
#10223
Rank
ยฃ12.18 M
Marketcap
ยฃ1.21
Share price
-1.23%
Change (1 day)
-51.81%
Change (1 year)

Revenue for Soligenix (SNGX)

Revenue in 2025 (TTM): N/A

In 2024 the company made a revenue of ยฃ0.09 Million a decrease over the revenue in the year 2023 that were of ยฃ0.2 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Soligenix from 1998 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) N/A-100%
2024 ยฃ0.09 M-53.8%
2023 ยฃ0.2 M-2.31%
2022 ยฃ0.2 M736.37%
2021 ยฃ0.02 M-98.26%
2020 ยฃ1.41 M-42.24%
2019 ยฃ2.45 M-21.5%
2018 ยฃ3.12 M-2.32%
2017 ยฃ3.19 M-62.23%
2016 ยฃ8.46 M43.12%
2015 ยฃ5.91 M30.8%
2014 ยฃ4.52 M131.44%
2013 ยฃ1.95 M0.46%
2012 ยฃ1.94 M-60.54%
2011 ยฃ4.93 M290.77%
2010 ยฃ1.26 M-27.5%
2009 ยฃ1.74 M10.4%
2008 ยฃ1.57 M148.85%
2007 ยฃ0.63 M-46.36%
2006 ยฃ1.18 M-31.57%
2005 ยฃ1.72 M
1999 ยฃ0 M-100%
1998 ยฃ0.24 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Cleveland BioLabs
CBLI
ยฃ0.47 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
ยฃ0.56 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
ยฃ35.67 BN/A๐Ÿ‡ซ๐Ÿ‡ท France
Pfizer
PFE
ยฃ47.13 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
ยฃ69.17 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
ยฃ0.06 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
ยฃ0.16 MN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ12.59 BN/A๐Ÿ‡ฎ๐Ÿ‡ฑ Israel